Aprea Therapeutics, Inc.
APRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781983
No open-market purchases or sales by Aprea Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $1.90M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 13, 2026
- $5.91M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +5 vs. previous quarter
- 27
- 13F valueReported value at the end of Q2 2026
- $1.90M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$12.6M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 525.2K
- Shares sold short
- Change
- −96.0K
- −15.5% vs. previous
- Days to cover
- 2.59
- At average daily volume
Superinvestors holding APRE, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding APRE at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Aprea Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2026 (view filing) | Mar 31 | 1 day | Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr | PPurchase | +62.0K | $0.81 | +$25.1K | –31.0K after | Derivative2 lots |
| Apr 1, 2026 (view filing) | Mar 31 | 1 day | Peters RichardDirector | PPurchase | +247.8K | $0.81 | +$100.4K | –123.9K after | Derivative2 lots |
| Feb 2, 2026 (view filing) | Jan 30 | 3 days | Gilad OrenPresident/CEO | PPurchase | +28.1K | $0.89 | +$25.0K | +8.1%373.7K after | |
| Feb 2, 2026 (view filing) | Jan 30 | 3 days | Gilad OrenPresident/CEO | PPurchase | +28.1K | – | – | –28.1K after | Derivative |
| Feb 2, 2026 (view filing) | Jan 30 | 3 days | Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr | PPurchase | +5.70K | $0.89 | +$5.07K | +20.6%33.4K after | |
| Feb 2, 2026 (view filing) | Jan 30 | 3 days | Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr | PPurchase | +5.70K | – | – | –5.70K after | Derivative |
| Dec 11, 2025 (view filing) | Dec 10 | 1 day | Duey MarcDirector | PPurchase | +21.5K | $1.17 | +$25.1K | +9.1%256.2K after | |
| Dec 11, 2025 (view filing) | Dec 10 | 1 day | Duey MarcDirector | PPurchase | +21.5K | – | – | –21.5K after | Derivative |
| Dec 11, 2025 (view filing) | Dec 10 | 1 day | Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr | PPurchase | +5.00K | $1.17 | +$5.85K | +22.0%27.7K after | |
| Dec 11, 2025 (view filing) | Dec 10 | 1 day | Hamill John P.SrVP/CFO/Prin Fin & Acct Ofcr | PPurchase | +5.00K | – | – | –5.00K after | Derivative |
Top 10 13F holders, Q2 2026
See all 27 holdersThe largest institutional positions in Aprea Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 1,015,541 | $814.8K | 0.07% | 00.0% | Unchanged |
| Vestal Point Capital, LP | 350,000 | $280.8K | 0.01% | 00.0% | Unchanged |
| Sphera Funds Management Ltd. | 270,000 | $216.6K | 0.03% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 205,760 | $165.1K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 105,800 | $84.9K | 0.00% | +80,700+321.5% | Added |
| Geode Capital Management, LLC | 74,869 | $60.1K | 0.00% | −44,262−37.2% | Reduced |
| Citadel Advisors LLC | 58,600 | $47.0K | 0.00% | +58,600 | New |
| BNP Paribas Arbitrage, SA | 45,211 | $36.3K | 0.00% | +5,394+13.5% | Added |
| Diadema Partners LP | 44,907 | $36.0K | 0.01% | +44,907 | New |
| Vanguard Fiduciary Trust Co | 38,464 | $30.8K | 0.00% | 00.0% | Unchanged |
Holders of 5% or more of APRE
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Aprea Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Soleus Private Equity Fund III, L.P. | 13G | 9.99%1.27M shares | New | Apr 1, 20261 filing | Apr 1, 2026 | SEC |
| Vestal Point Capital, LP | 13G | 9.90%22.7M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |
| Squadron Capital Management LLC | 13G | 9.90%1.27M shares | New | Apr 7, 20261 filing | Apr 7, 2026 | SEC |
| Hirschman Orin | 13G/A | 9.90%1.19M shares | 0.00 ppfrom 9.90% | Mar 3, 20235 filings | Apr 27, 2026 | SEC |